These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22503954)

  • 1. Oral delivery of therapeutic protein/peptide for diabetes--future perspectives.
    Rekha MR; Sharma CP
    Int J Pharm; 2013 Jan; 440(1):48-62. PubMed ID: 22503954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M; Rayfield EJ
    Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
    Chuang EY; Nguyen GT; Su FY; Lin KJ; Chen CT; Mi FL; Yen TC; Juang JH; Sung HW
    Biomaterials; 2013 Oct; 34(32):7994-8001. PubMed ID: 23891516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the oral delivery of insulin.
    Ramesan RM; Sharma CP
    Recent Pat Drug Deliv Formul; 2014; 8(2):155-9. PubMed ID: 24867419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel strategies in the oral delivery of antidiabetic peptide drugs - Insulin, GLP 1 and its analogs.
    Ismail R; Csóka I
    Eur J Pharm Biopharm; 2017 Jun; 115():257-267. PubMed ID: 28336368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide for once-weekly administration.
    Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects.
    Araujo F; Shrestha N; Granja PL; Hirvonen J; Santos HA; Sarmento B
    Curr Pharm Biotechnol; 2014; 15(7):609-19. PubMed ID: 25219868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
    Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and strategies for moving patients to injectable medications.
    Siminerio L
    Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
    [No Abstract]   [Full Text] [Related]  

  • 11. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems.
    Card JW; Magnuson BA
    Am J Physiol Gastrointest Liver Physiol; 2011 Dec; 301(6):G956-67. PubMed ID: 21921287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive insulin delivery: the great potential of cell-penetrating peptides.
    Kamei N; Nielsen EJ; Khafagy el-S; Takeda-Morishita M
    Ther Deliv; 2013 Mar; 4(3):315-26. PubMed ID: 23442079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments.
    Krol S; Ellis-Behnke R; Marchetti P
    Nanomedicine; 2012 Sep; 8 Suppl 1():S69-76. PubMed ID: 22640905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments.
    Krol S; Ellis-Behnke R; Marchetti P
    Maturitas; 2012 Sep; 73(1):61-7. PubMed ID: 22209199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using prandial insulin to achieve glycemic control in type 2 diabetes.
    Dailey GE
    J Fam Pract; 2007 Sep; 56(9):735-42. PubMed ID: 17764645
    [No Abstract]   [Full Text] [Related]  

  • 18. Nanoparticle strategies for the oral delivery of insulin.
    Damgé C; Reis CP; Maincent P
    Expert Opin Drug Deliv; 2008 Jan; 5(1):45-68. PubMed ID: 18095928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
    Unger J; Nadeau DA
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B
    Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.